10,558 Shares in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Purchased by Atria Investments Inc

Atria Investments Inc bought a new stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the fourth quarter, Holdings Channel.com reports. The institutional investor bought 10,558 shares of the company’s stock, valued at approximately $58,000.

Several other hedge funds also recently bought and sold shares of MRVI. FNY Investment Advisers LLC raised its stake in shares of Maravai LifeSciences by 600.0% in the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock valued at $38,000 after acquiring an additional 6,000 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Maravai LifeSciences in the 3rd quarter valued at approximately $105,000. Neo Ivy Capital Management purchased a new stake in Maravai LifeSciences in the third quarter valued at approximately $136,000. XTX Topco Ltd acquired a new position in Maravai LifeSciences during the third quarter worth $193,000. Finally, Intech Investment Management LLC purchased a new position in shares of Maravai LifeSciences during the third quarter worth $200,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Insider Activity at Maravai LifeSciences

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the transaction, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54. This represents a 12.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.63% of the stock is currently owned by corporate insiders.

Maravai LifeSciences Trading Down 5.8 %

Shares of NASDAQ:MRVI opened at $2.43 on Thursday. Maravai LifeSciences Holdings, Inc. has a 52 week low of $2.25 and a 52 week high of $11.56. The company’s 50 day moving average is $4.09 and its two-hundred day moving average is $5.90. The company has a market cap of $613.64 million, a PE ratio of -1.48 and a beta of -0.08. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. The Goldman Sachs Group downgraded Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their price objective for the company from $7.00 to $4.25 in a report on Thursday, December 5th. Robert W. Baird downgraded Maravai LifeSciences from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $9.00 to $3.00 in a research report on Wednesday, February 26th. Guggenheim assumed coverage on shares of Maravai LifeSciences in a research report on Thursday, December 19th. They set a “neutral” rating on the stock. Bank of America dropped their price objective on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Finally, Baird R W lowered shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $9.28.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.